![Charlotte Lovatt BSc, PhD, AFHEA](https://profiles-cardiff.imgix.net/attachments/3332?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Charlotte Lovatt
(she/her)
BSc, PhD, AFHEA
Teams and roles for Charlotte Lovatt
Post-doctoral Research Associate
Overview
As a post-doctoral researcher in the Viral ImmunoTherapies and Advanced therapeutics Lab (VITAL) my work focuses on generating oncolytic viruses which target pancreactic cancer cells and deliver immunotherapies directly to the tumour. By using a targeted oncolytic virus that only infects pancreatic cancer cells, we hope to "heat up" the pancreatic tumour environment and induce a tumour-specific immune response whilst reducing harmful side effects often seen with systemic therapies.
My PhD, which focused on developing new immunotherapies for lung cancer, has given me a strong foundation in immuno-oncology research. Prior to my current role, my post-doctotral research within the VITAL lab initially focused on investigating virus:host interactions underpinning the ultra-rare thrombotic events following adenoviral SARS-CoV vaccination. This research expertise allows me to uniquely bride the domains of immuno-onconoly and virology.
Publication
2025
- Lovatt, C. et al. 2025. Investigating endothelial cell transduction and hexon: platelet factor 4 binding of ChAdOx1 in the context of vaccine-induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis 23 (10), pp.3319-3326. (10.1016/j.jtha.2025.06.006)
- Nicolson, P. et al., 2025. Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: A comprehensive synopsis. Efficacy and Mechanism Evaluation 12 (7)(10.3310/ffss9010)
2024
- Lovatt, C. et al. 2024. Pigment epithelium derived factor drives melanocyte proliferation and migration in neurofibromatosis café au lait macules. Skin Health and Disease 4 (5) e394. (10.1002/ski2.394)
- Gardner, J. et al., 2024. Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. npj Vaccines 9 (1) 99. (10.1038/s41541-024-00895-z)
2023
- Lovatt, C. and Parker, A. L. 2023. Oncolytic viruses and immune checkpoint inhibitors: the "hot" new power couple. Cancers 15 (16) 4178. (10.3390/cancers15164178)
- Bates, E. A. et al. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15 (5) 1086. (10.3390/v15051086)
2022
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132 (21) e150750. (10.1172/JCI150750)
- Lovatt, C. 2022. Evaluating the role of CD200 in non-small cell lung carcinoma immune evasion. PhD Thesis , Cardiff University.
Articles
- Lovatt, C. et al. 2025. Investigating endothelial cell transduction and hexon: platelet factor 4 binding of ChAdOx1 in the context of vaccine-induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis 23 (10), pp.3319-3326. (10.1016/j.jtha.2025.06.006)
- Nicolson, P. et al., 2025. Understanding mechanisms of thrombosis and thrombocytopenia with adenoviral SARS-CoV-2 vaccines: A comprehensive synopsis. Efficacy and Mechanism Evaluation 12 (7)(10.3310/ffss9010)
- Lovatt, C. et al. 2024. Pigment epithelium derived factor drives melanocyte proliferation and migration in neurofibromatosis café au lait macules. Skin Health and Disease 4 (5) e394. (10.1002/ski2.394)
- Gardner, J. et al., 2024. Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines. npj Vaccines 9 (1) 99. (10.1038/s41541-024-00895-z)
- Lovatt, C. and Parker, A. L. 2023. Oncolytic viruses and immune checkpoint inhibitors: the "hot" new power couple. Cancers 15 (16) 4178. (10.3390/cancers15164178)
- Bates, E. A. et al. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15 (5) 1086. (10.3390/v15051086)
- Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132 (21) e150750. (10.1172/JCI150750)
Thesis
- Lovatt, C. 2022. Evaluating the role of CD200 in non-small cell lung carcinoma immune evasion. PhD Thesis , Cardiff University.
Biography
l Cardiff University School of Medicine
- Post-doctoral Research Associate (Pancreatic Cancer Research Fund) May 2023 - present: Establishing "organoid hospitals" as pre-clinical models to evaluate precision virotherapies
- Post-doctoral Research Associate (NIHR) Jan 2022 - May 2023: Understanding mechanisms of thrombosis and thrombocytopenia in COVID-19 and with SARS-CoV-2 vaccines
European Cancer Stem Cell Research Institute
- PhD (KESS2) Oct 2018 - May 2022: Evaluating the role of CD200 in non-small cell lung carcinoma immune evasion
Cardiff Univeristy School of Biosciences
- Undergraduate degree Oct 2014 - Oct 2018: Biomedical Sciences (Anatomy) with a professional training year
- Professional training year Oct 2016 - Jul 2017: NF1 driver mutations in metastatic melanoma are associated with deregulated PEDF expression
Contact Details
Cancer Genetics Building, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
Research themes
Specialisms
- Cancer immunology
- Cancer therapy
- pancreatic cancer
- Virotherapy
- Organoids